Menu

• Tuberculosis
• The End TB Strategy
• Areas of work
  • Detection and diagnosis
    • Early detection
    • Diagnostics
      • Policy
      • Global laboratory initiative
      • Supranational Reference Laboratory Network
    • Active case finding
    • Contact investigation
    • Outbreak management
  • Treatment and care
    • Treatment of drug-resistant TB
    • New drugs
    • Comorbidities
    • Ethical issues
  • Preventive care
    • Latent tuberculosis infection (LTBI)
    • Infection control
    • Vaccines
  • Drug-resistant TB
    • MDR-TB surveillance
    • Treatment of drug-resistant TB
    • Public-private mix for drug-resistant TB
  • TB and HIV
    • Advocacy
    • Research
    • Scale-up
    • Task Force
    • People who use drugs
  • Childhood TB
  • Addressing needs of vulnerable populations
    • Poverty
    • Refugees
    • Gender
    • Prisons
    • Social determinants
    • People who use drugs
  • Technical support to countries
    • About technical support coordination
    • Partnering with Global Fund
    • Support to countries
    • Technical expertise
  • Community engagement: ENGAGE-TB
    • About ENGAGE-TB
    • Country experiences
    • ENGAGE-TB meetings and events
    • Civil Society Task Force on TB
  • Public-Private Mix
  • Monitoring and evaluation
    • TB data
    • Global Task Force on TB impact measurement
    • MDR-TB surveillance data
    • Financing
  • Digital health
    • Global Task Force on Digital Health for TB
    • TPPs and priority digital health products for TB
  • Research
  • Zoonotic TB
• TB publications
• TB data
• News, events and features
• About us

Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach

WHO/HTM/TB/2008.404

The guidelines

• English [pdf 3Mb]
• Chinese [pdf 2Mb]
• Russian [pdf 854kb]

WHO/HTM/TB/2008.404

Policy brief

• English [pdf 353kb]
• Russian [pdf 554kb]
• Spanish [pdf 379kb]